Arete Wealth Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

Arete Wealth Advisors’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-19,450	Closed	-$148K	–	391
2025 Q3	$148K	Hold	19,450	–	–	0.01%	740
2025 Q2	$174K	Sell	19,450 -750	-4%	-$6.99K	0.01%	695
2025 Q1	$152K	Hold	20,200	–	–	0.01%	686
2024 Q4	$152K	Buy	20,200 +8,150	+68%	+$61.9K	0.01%	711
2024 Q3	$92K	Sell	12,050 -10,150	-46%	-$77.2K	0.01%	675
2024 Q2	$137K	Buy	+22,200	New	+$123K	0.01%	681
2024 Q1	–	Sell	-22,550	Closed	-$135K	–	412
2023 Q4	$135K	Sell	22,550 -750	-3%	-$4.35K	0.01%	699
2023 Q3	$165K	Buy	23,300 +9,150	+65%	+$65.7K	0.03%	446
2023 Q2	$100K	Sell	14,150 -9,823	-41%	-$78.8K	0.01%	631
2023 Q1	$200K	Buy	23,973 +350	+1%	+$3.37K	0.02%	580
2022 Q4	$271K	Buy	+23,623	New	+$295K	0.02%	484

Other funds holding BCRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Arete Wealth Advisors's BCRX Position: Q4 2025 in Review

Arete Wealth Advisors sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2025, closing a stake of 19,450 shares — an estimated $148K sold.

Arete Wealth Advisors first reported a position in BCRX in Q4 2022 and held it in 11 quarters. The position peaked at $271K in Q4 2022. 272 funds tracked by Wall St. Rank hold BCRX as of Q4 2025.

Arete Wealth Advisors reported no remaining BioCryst Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Arete Wealth Advisors sold 19,450 BioCryst Pharmaceuticals shares in Q4 2025, an estimated $148K.
Arete Wealth Advisors first reported a position in BioCryst Pharmaceuticals in Q4 2022 and held it in 11 quarters.
Arete Wealth Advisors's BioCryst Pharmaceuticals position peaked at $271K in Q4 2022.
272 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2025.

Based on Arete Wealth Advisors's 13F filing for Q4 2025, filed 13 Feb 2026.